G. D. Searle Pharmaceutical
G. D. Searle Pharmaceutical is a wholly-owned trademark of growing pharmaceutical company, Pfizer. The company currently operates as a distribution trademark for various pharmaceuticals that were developed by G. D. Searle & Company referred to as Searle. In 1985, a merger with Monsanto, Searle was a company leading in manufacturing of life sciences, specifically pharmaceuticals, agriculture, and animal health.
The Research and Development team of the company G. D. Searle Pharmaceutical files a patent application in 1993 for celecoxib. After developing, it became the first selective COX-2 inhibitor to be approved by the FDA on December 31, 1998. It is the key reason for Pfizer's acquisition of Pharmacia. The company is most notable for having developed the first female birth control pill, and the artificial sweetener NutraSweet.
The company offers effective drugs and nuclear medicine imaging equipment. G. D. Searle Pharmaceutical is known for its release of Enovid in 1960, which is the first commercial oral contraceptive. The company also powered with its release of the first bulk laxative, Metamucil, in 1934, Dramamine, for motion sickness, the COX-2 inhibitors Celebrex and Bextra, Ambien for insomnia, and NutraSweet, an artificial sweetener, in 1965.
There are no products to list.